Direct retrospective comparison of adalimumab and infliximab in preventing early postoperative endoscopic recurrence after ileocaecal resection for XXXX : results from the MULTIPER database.

@entity1 @entity30 @entity5 @entity39
BACKGROUND AND AIMS: Both adalimumab [ADA] and infliximab [IFX] seem to be effective in the prevention of early postoperative endoscopic recurrence [EPER] after ileocaecal resection in @entity30 [ @entity30 ] @entity1 . There is lack of data with direct comparison between the two agents in the postoperative scenario. The aim of this study was to compare the rates of EPER in @entity1 treated with ADA and IFX after ileocaecal resection for @entity30 . METHODS: This was a multicentre retrospective analysis of EPER rates in @entity30 @entity1 after ileocaecal resections, from seven referral centres in three countries. Endoscopic recurrence was defined as Rutgeerts' score >=  i2. The @entity1 were allocated according to treatment to two groups: ADA or IFX. The EPER rates were compared between the two treatment groups. RESULTS: Among the 168 @entity1 included in the database, 96 received anti- @entity5 @entity39 factor [TNF] agents after resection [37 in the ADA and 59 in the IFX groups] and were included in this comparative study. The groups were comparable in all baseline characteristics, mainly age, gender, previous resections, perianal @entity30 , and mono or combination therapy. EPER was identified in 9/37 [24.32%] in the ADA group vs 16/59 [27.12%] in the IFX group [p = 0.815]. CONCLUSIONS: In this retrospective direct comparison between ADA and IFX therapy after ileocaecal resection, there was no significant difference between the two anti-TNF agents in terms of EPER rates. However, prospective randomised studies are needed to confirm these data and better define the role of each agent in the prevention of EPER.
